PM Modi visits Vaccine manufacturing facility in Ahmedabad & Hyderabad
Prime Minister Narendra Modi was welcomed by Pankaj Patel – the Chairman and Sharvil Patel- Managing Director of Zydus Cadila Pharmaceuticals on his arrival at the Zydus Biotech Park in Ahmedabad. During the half an hour meeting, Prime Minister Modi discussed the process of vaccine development, its trials and distribution of the final product. Zydus Cadila Pharmaceutical’s vaccine development facility at Zydus Biotech Park is working on ZyKoV-D, a Covid19 vaccine candidate. Zydus Cadila is expected to submit the results of its Phase 2 trials next week, which will ascertain the safety, dose and efficacy of the potential vaccine. It will also apply for Phase three clinical trials of its experimental COVID-19 vaccine in December. The company is expected to roll out the final product by March next year after the success of all trials.
After his visit to the Zydus Biotech Park in Ahmedabad, in a tweet, Mr Modi said that he had complimented the team behind this effort for their work. He said, the Government of India is actively working with them to support them in this journey.
From Ahmedabad the Prime Minister then flew to Hyderabad and arrived at the Air Force Station at Hakimpet. He was welcomed by State Chief Secretory Somesh Kumar, State DGP Mahender Reddy Medchal Malkajgiri Collector Swetha Mohanthy among other senior officials. Our Hyderabad Correspondent reports that the Prime Minister reached Bharat Biotech International Limited in the Genome Valley located near Shamirpet on the outskirts of Hyderabad. The Prime Minister met with Scientists and discussed with them about the roadmap of the vaccine production and supply.
Prime Minister Narendra Modi has reached the Bharat Biotech International Limited (BBIL) located at the Genome Valley on the outskirts of Hyderabad and reviewing the development and manufacturing process relating to COVID-19 Vaccine.
He has taken up rounds to the vaccine manufacturing installations where the processes are underway for COVID-19 Vaccine, called Covaxin and visiting the Bio-Safety Level 3 laboratory. He is interacting with the senior scientists and other concerned at the BBIL and being briefed about the progress made so far relating to manufacturing of the Covaxin.